In a big win for Actavis plc, the U.S. Court of Appeals for the Federal Circuit on Wednesday reaffirmed a lower court decision that Actavis’ patent for a popular low-estrogen birth control pill is valid and enforceable.
The drug, the brand-name contraceptive Lo Loestrin, has the lowest estrogen dose of any U.S.-approved oral contraceptive and has been extremely popular since its introduction a few years ago, with sales of $250 million last year. Wednesday’s ruling promises to extend Actavis’ market exclusivity on Lo Loestrin for 15 years, until the company’s patent expires in 2029.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
